TB-500 + GHK-Cu

Overview

Grey-market vendor blend combining TB-500 (a synthetic heptapeptide fragment of Thymosin Beta-4, not full-length Tβ4) and GHK-Cu (a copper tripeptide). This blend is not clinically validated; evidence is extrapolated from individual-component research, and no human trials of the combination exist.

Mechanism of Action

Proposed (not validated) rationale: the TB-500 fragment is marketed as mimicking Tβ4's actin-binding and cell-migration effects, though most published Tβ4 wound-healing data uses the full protein, not the TB-500 fragment. GHK-Cu has cosmetic-grade evidence from topical studies. No synergy between the two has been demonstrated.

Research Summary

No clinical trials of the TB-500 + GHK-Cu combination exist. TB-500 itself lacks human efficacy data; GHK-Cu's evidence base is primarily topical/cosmetic. Subcutaneous use of either for musculoskeletal healing is not validated.

Dosing Information

Reported Side Effects

• See individual TB-500 and GHK-Cu profiles